AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.76 USD
+0.13 (3.58%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABCL 3.76 +0.13(3.58%)
Will ABCL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABCL
AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates
ABCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Techne (TECH) Q2 Earnings and Revenues Lag Estimates
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
Earnings Preview: AbCellera Biologics Inc. (ABCL) Q3 Earnings Expected to Decline
Other News for ABCL
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
AbCellera management to meet with Truist
AbCellera management to meet with Truist
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024